Following montmorillonite and norfloxacin, another drug has joined the wave of hoarding?

【Pharmaceutical Network Pharmaceutical Stock Market】Recently, montmorillonite scatter and norfloxacin have set off a rush to buy, but these drugs have not been searched, and another drug has joined the wave of hoarding, that is, coenzyme Q10
.
Many media reported that Coenzyme Q10 was in short supply in offline pharmacies, and pharmacies arrived less, and each arrival was quickly snapped up
.
On some large e-commerce platforms, coenzyme Q10 has also been out of stock due to the surge in demand, and the out-of-stock phenomenon has improved on the 9th, with prices ranging from
200-400 yuan.
So, what is Coenzyme Q10? According to the data, this drug, commonly known as vitamin Q, is a compound integrating medical and nutritional health care, which has the effect of antioxidant, activating cellular respiration, improving human immunity, etc.
, and has application value
in food, medicine, cosmetics and other fields.
The analysis believes that the rush to buy coenzyme Q10 may be closely related to myocarditis
.
Recently, it has been rumored on the Internet that coenzyme Q10 has the effect of preventing myocarditis, resulting in the drug being in short supply
.
However, the industry pointed out that coenzyme Q10 only plays an auxiliary role in myocarditis, can help the recovery of myocardium, and cannot prevent myocarditis
.
It is understood that China is a big producer of coenzyme Q10 products, and most of the coenzyme Q10 raw materials on the market are produced in China
.
According to data from Zhiyan Consulting, affected by the sharp increase in export orders in 2021, domestic coenzyme Q10 production increased to 1321.
99 tons
.
As of 2021, the demand for coenzyme Q10 in China has increased to 212.
69 tons, and the compound growth rate of China's coenzyme Q10 demand has reached 18.
52%
since 2014.
In 2021, the market size of China's coenzyme Q10 industry increased to 426 million yuan, and the compound growth rate of the market size of China's coenzyme Q10 industry since 2014 was 21.
82%.

Affected by the increase in product demand, coenzyme Q10-related concept stocks have also risen in recent days
.
As of the close of trading on January 9, Lily shares rose 2.
95% to 44.
7 yuan; Jindawei rose 1.
02% to 22.
84 yuan; while Xinhecheng and Zhejiang Pharmaceutical fell slightly
.
According to public information, King Dawei is the leading manufacturer of coenzyme Q10 raw materials in China, and the company's production capacity of coenzyme Q10 reached 600 tons
at the end of 2021.
On January 6, King Dawei mentioned on the investor interactive platform that due to the increase in consumption, the company's orders for coenzyme Q10 have increased
recently.
On January 9, King Dawei replied to investors on the investor interactive platform that in the face of the current situation of serious shortage of coenzyme Q10 in Taobao and JD.
com, the company's products still have 200mg specifications to purchase, and other specifications will be replenished
as soon as possible.
In addition to King Dawei, the scale of Xinhecheng's production capacity is also relatively high.

Xinhecheng said on the interactive platform on January 5 that the company's current annual production capacity of coenzyme Q10 is 300 tons
.
In addition, the manufacturers of coenzyme Q10 raw materials also include Shenzhou Biotechnology, Zhejiang Pharmaceutical, etc
.
Tomson By-Health, Lily Co.
, Ltd.
, etc.
mainly produce coenzyme Q10 preparations
.
From the public information, Zhejiang Pharmaceutical, Lily Co.
, Ltd.
and other companies have also confirmed in interviews with relevant media that the demand for coenzyme Q10 has risen recently, and Tomson By-Health and others said that they will make timely production adjustments
with changes in demand.
According to reports, By-Health Coenzyme Q10 raw materials are imported from Japan and usually sign an annual purchase agreement
.
The company said that the price of raw materials has not increased for the time being, and the current supply of raw materials is stable, and the hot sales of terminal products are only half a month, and it takes a certain amount of time
to transmit to the upstream.
Similarly, the price of the company's preparations did not increase
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.